In this webinar, we discussed how to interpret your pathology report. We covered interpretation of all parts of a pathology report, beginning with understanding the final diagnosis and diagnostic comment.
With the advent of Imatinib, tremendous progress has been made in the treatment of patients with GIST.
A new blood testing technology may lead to major changes in treatment of Gastrointestinal Stromal Tumors. In a study presented in April by Dr. George Demetri of the Dana-Farber Cancer Institute at the American Association for Cancer Research annual meeting, the blood test was shown to be more effective than traditional biopsies in identifying secondary mutations in GIST.
By Drs. Sebastian Bauer, West German Cancer Center, University of Essen, Germany and Jonathan Fletcher, Brigham & Women’s Hospital, Harvard University, LRG Research Team Researchers talk plainly about microGISTs, how this cancer develops and what all [...]
Written by Jennifer Wright April, 2011 - This article is a summary of “Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations” in the Proceedings of the National Academy of Sciences [...]
Sept, 2007 - A diverse group of researchers has found the genetic defects that cause a rare type of familial GIST called “Carney-Stratakis syndrome”. This syndrome has some similarities to Carney’s Triad but it [...]
